612 results on '"Vannucchi, Alessandro M"'
Search Results
2. Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial
3. Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis.
4. Erratum to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
5. One thousand patients with essential thrombocythemia: the Florence-CRIMM experience
6. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities
7. Functional relevance of circRNA aberrant expression in pediatric acute leukemia with KMT2A::AFF1 fusion
8. MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
9. Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials
10. The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation‐enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis
11. CALR mutations possess unique prognostic relevance in myelofibrosis—before and after transplant
12. Molecular risk stratification of myeloproliferative neoplasms
13. Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
14. A globally applicable “triple A” risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count
15. MPN-295 Avapritinib in Patients With Advanced Systemic Mastocytosis (AdvSM): Efficacy and Safety Analyses from the Phase 2 PATHFINDER Study With 2-Year Follow-Up
16. POSTER: MPN-295 Avapritinib in Patients With Advanced Systemic Mastocytosis (AdvSM): Efficacy and Safety Analyses from the Phase 2 PATHFINDER Study With 2-Year Follow-Up
17. MPN-193 Incidence of Blast Phase in Myelofibrosis According to Anemia Severity
18. MPN-404 Safety and Efficacy of Luspatercept for the Treatment of Anemia in Patients With Myelofibrosis: Results From the ACE-536-MF-001 Study
19. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study
20. POSTER: MPN-404 Safety and Efficacy of Luspatercept for the Treatment of Anemia in Patients With Myelofibrosis: Results From the ACE-536-MF-001 Study
21. POSTER: MPN-193 Incidence of Blast Phase in Myelofibrosis According to Anemia Severity
22. S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX
23. Incidence of blast phase in myelofibrosis according to anemia severity
24. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials
25. Myeloid sarcoma: more and less than a distinct entity
26. Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network
27. JAK2 inhibitor treatment of anemia in myelofibrosis
28. Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group
29. Supplemental Table S2 from Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis
30. Supplemental Table S1 from Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis
31. Supplemental Table S2 from Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis
32. Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT‐I and COMFORT‐II studies
33. Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis
34. Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
35. Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real‐life setting: An Italian MYNERVA Project
36. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
37. ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms
38. The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis
39. International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms
40. Diagnostic and therapeutic challenges in mast cell sarcoma
41. Anemia in myelofibrosis: Current and emerging treatment options
42. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
43. Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial
44. FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLNFGFR1): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated Patients
45. Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor
46. Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)
47. Haploinsufficiency of Calreticulin Causes Dysregulation of Hematopoiesis and Results in a Myeloproliferative Phenotype in an in-Vivo Mouse Model
48. Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial
49. Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
50. INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis: A Phase 1 Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.